Of note, the expression of TGF-β in RdB/IL12/DCN-treated tumor tissues was significantly lower than in tissues treated with RdB, RdB/IL12 or RdB/DCN, indicating that IL-12 and DCN may function as adjuvant to restore the immune stimulatory function of IL-12 and attenuate immunosuppressive TGF-β expression (Figure 5B). The gene discussed is TGFB1; the disease is neoplasm.